Oppenheimer Maintains Outperform on Wave Life Sciences, Lowers Price Target to $29

Benzinga · 3d ago
Oppenheimer analyst Cheng Li maintains Wave Life Sciences (NASDAQ:WVE) with a Outperform and lowers the price target from $32 to $29.